Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Fürstenwalde – page 135

1 727 clinical trials in Fürstenwalde, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Fürstenwalde at a glance
1 727
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 727 trials in Fürstenwalde

Open in trial search

Study on Ribociclib and Drug Combination for Patients with Advanced HER2-Negative, Hormone Receptor Positive Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Institut Für Frauengesundheit GmbH

Study on Long-term Effects and Safety of Odevixibat in Children with Biliary Atresia

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Odevixibat
  • Sponsor:Ipsen Pharma

Plasma cell myeloma

Not recruiting

Study on Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Low-Risk Multiple Myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Schleswig-Holstein AöR

Study of Pembrolizumab and Cisplatin for Patients with Stage III-IVA Resectable Head and Neck Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Axial spondyloarthritis+1

Not recruiting

Study on Upadacitinib for Adults with Active Axial Spondyloarthritis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Plasma cell myeloma

Not recruiting

Study to Compare Mezigdomide, Carfilzomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Celgene Corp.

Tendon disorder

Not recruiting

Study on the Safety and Effects of NGI226 Microparticles for Patients with Achilles Tendinopathy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:NGI226
  • Sponsor:Novartis Pharma AG

Renal cell carcinoma

Not recruiting

Study on the Safety and Effectiveness of Pembrolizumab for Patients with Kidney Cancer After Surgery

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Study of Pembrolizumab as Additional Treatment for Patients with High-Risk Locally Advanced Cutaneous Squamous Cell Carcinoma After Surgery and Radiation

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Hepatitis D

Not recruiting

Study on Bulevirtide Treatment for Patients with Chronic Hepatitis D

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bulevirtide
  • Sponsor:Gilead Sciences Inc.

Study of LY3819469 for Adults with High Lipoprotein(a) Levels

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:LY3819469 sodium
  • Sponsor:Eli Lilly & Co.

Study of Pembrolizumab and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Fürstenwalde

What the registry says about research in the country

01 Respiratory Tract Diseases

Clinical research in Fürstenwalde Spree is focused on respiratory tract diseases, with all active studies centered on asthma and its more severe forms. These trials are looking at new treatment options, safety, and signs of better disease control for people with difficult-to-manage asthma.

  • Asthma and uncontrolled asthma
  • Severe eosinophilic asthma and eosinophilic phenotype
  • Moderate to severe controlled asthma under current guideline-based care
  • Testing new therapies and comparing them with existing treatments

The research includes studies of inhaled and biologic approaches, with an emphasis on improving symptom control, evaluating long-term safety, and measuring airway inflammation markers.

02 Asthma Treatment Safety and Tolerability

One part of the local trial landscape examines how well new asthma treatments are tolerated, especially in people already living with persistent disease. These studies help determine whether emerging options can offer benefits while remaining safe for everyday use.

  • Asthma treatment safety
  • Comparing different inhaled therapy formulations
  • Assessing long-term safety in ongoing care

This work supports clearer decisions about whether new therapies can be used comfortably and reliably in routine respiratory medicine.

03 Severe Eosinophilic Asthma

Several studies are dedicated to severe eosinophilic asthma, a more advanced form of asthma linked to ongoing inflammation. The goal is to see whether newer biologic treatments can improve control for patients who have already responded to specialized care.

  • Severe eosinophilic asthma
  • Evaluating biologic treatments for better disease control
  • Studying patients who benefited from prior anti-IL-5 or anti-IL-5R therapy

These trials aim to refine treatment choices for people with persistent eosinophilic airway inflammation and ongoing symptoms.

04 Biologic Therapies for Asthma

The research portfolio also includes studies of targeted biologic therapies for asthma, especially for patients with frequent symptoms or severe inflammatory disease. These trials are designed to test whether newer medicines can offer stronger and longer-lasting benefit than current options.

  • Biologic treatment strategies
  • Severe asthma management
  • Comparing new targeted therapies with established care

This area highlights a broader move toward more precise respiratory research that matches therapy to the underlying disease pattern.

05 Inflammation Markers and Asthma Control

Another important focus is the study of markers that reflect airway inflammation in asthma. By observing changes such as FeNO, researchers can better understand how well a treatment is affecting the underlying disease process.

  • Fraction of exhaled nitric oxide (FeNO)
  • Uncontrolled asthma
  • Evaluating whether new therapy can reduce airway inflammation

This kind of research helps improve both diagnosis and treatment monitoring in respiratory tract disease care.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.